The AlphaLISA™ human PCSK9 and human LDLR binding assay uses anti-6xHis AlphaLISA Acceptor beads to capture the His-tagged PCSK9 and Streptavidin-coated Donor beads to capture the biotinylated LDLR. When PCSK9 binds LDLR, excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Formats:

• Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 20 μL reaction volume.
• Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 20 μL reaction volume.

AlphaLISA features:

• No-wash steps, no separation steps
• Ease-of-use: few addition steps, fast assay development
• Broad range of affinities: detect strong or weak interactions, from pM to mM affinity
• Distance: measure very large protein or antibody complexes – spanning up to 200 nm or more
• High avidity: multiple binding sites on each bead enables use of nanomolar concentrations of antibodies or proteins, as well as use of low affinity binders

Human proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as FH3, HCHOLA3, NARC1 and PC9, is a crucial player in the regulation of plasma cholesterol homeostasis. PCSK9 binds to low density lipoprotein receptor (LDLR) and promotes PCSK9 lysosomal degradation in the liver, thereby reducing LDL clearance. Studies of PCSK9-LDLR binding have aided in the development of therapeutic anti-PCSK9 antibodies that effectively block this interaction at the cell surface. Therefore, blocking PCSK9 and LDLR binding has been considered a promising therapeutic target against cardiovascular disease.